Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Pliant Therapeutics (PLRX) Equity Ratio (2019 - 2025)

Pliant Therapeutics (PLRX) has disclosed Equity Ratio for 7 consecutive years, with 0.72 as the latest value for Q3 2025.

  • On a quarterly basis, Equity Ratio changed N/A to 0.72 in Q3 2025 year-over-year; TTM through Sep 2025 was 0.72, a N/A change, with the full-year FY2024 number at 0.77, down 17.16% from a year prior.
  • Equity Ratio was 0.72 for Q3 2025 at Pliant Therapeutics, down from 0.75 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.96 in Q1 2021 to a low of 0.72 in Q3 2025.
  • A 5-year average of 0.88 and a median of 0.9 in 2022 define the central range for Equity Ratio.
  • Peak YoY movement for Equity Ratio: increased 6.55% in 2023, then fell 17.16% in 2024.
  • Pliant Therapeutics' Equity Ratio stood at 0.9 in 2021, then decreased by 0.68% to 0.89 in 2022, then grew by 3.47% to 0.92 in 2023, then decreased by 17.16% to 0.77 in 2024, then decreased by 5.47% to 0.72 in 2025.
  • Per Business Quant, the three most recent readings for PLRX's Equity Ratio are 0.72 (Q3 2025), 0.75 (Q1 2025), and 0.77 (Q4 2024).